Xenon Pharmaceuticals of Vancouver has received Cnd$7 million in strategic funding from Roche, as part of a larger research and licensing agreement for protein-based inhibitors of hemojuvelin. www.xenon-pharma.com
Xenon Pharmaceuticals of Vancouver has received Cnd$7 million in strategic funding from Roche, as part of a larger research and licensing agreement for protein-based inhibitors of hemojuvelin. www.xenon-pharma.com
Copyright PEI Media
Not for publication, email or dissemination